Dane Karr, Ph.D.
VP, Preclinical Development
Dane Karr, Ph.D. has served as Vice President, Preclinical Development since 2020. Prior to joining Nurix, he served as Senior Director of Preclinical Development at Principia Biopharma, a late-stage biopharmaceutical company focused on developing novel therapies for serious immune mediated diseases. Dr. Karr has more than 20 years of experience leading biopharmaceutical departments and advancing multiple compounds from R&D to clinical development. He has led teams in directing the discovery and development of new products including Vibativ, BREO Ellipta, Anoro Ellipta, Plazomycin and Rilzabrutinib. He received his Ph.D. in chemistry from the University of California, Los Angeles and his B.S. in chemistry from The University of Georgia.